Department of Medical Physiology, Division Heart & Lungs, University Medical Center Utrecht, 3584 CM Utrecht, The Netherlands.
Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.
Int J Mol Sci. 2021 Dec 21;23(1):57. doi: 10.3390/ijms23010057.
In arrhythmogenic cardiomyopathy (ACM) pathogenic variants are found in genes encoding desmosomal proteins and in non-desmosomal genes, such as (, p.Arg14del variant). Previous research showed that plakoglobin protein levels and localization in the cardiac tissue of ACM patients, and p.Arg14del patients diagnosed with an ACM phenotype, are disturbed. Moreover, the effects of pathogenic variants in desmosomal genes are reflected in non-cardiac tissues like buccal mucosa cells (BMC) which could serve as a promising new and non-invasive tool to support diagnosis. We collected the BMC of 33 ACM patients, 17 p.Arg14del patients and 34 controls, labelled the BMC with anti-plakoglobin antibodies at different concentrations, and scored their membrane labelling. We found that plakoglobin protein levels were significantly reduced in BMC obtained from diagnosed ACM patients and preclinical variant carriers when compared to controls. This effect was independent from age and sex. Moderate to strong correlations were found with the revised 2010 Task Force Criteria score which is commonly used for ACM diagnosis (r = -0.67, = 64, < 0.0001 and r = -0.71, = 64, < 0.0001). In contrast, plakoglobin scores in p.Arg14del patients were comparable to controls ( > 0.209), which suggests differences in underlying etiology. However, for the individual diagnosis of the 'classical' ACM patient, this method might not be discriminative enough to distinguish true patients from variant carriers and controls, because of the high interindividual variability.
在心律失常性心肌病 (ACM) 中,致病性变异存在于编码桥粒蛋白的基因和非桥粒基因中,例如 (,p.Arg14del 变异)。先前的研究表明,ACM 患者心脏组织中的桥粒蛋白水平和定位以及诊断为 ACM 表型的 p.Arg14del 患者的桥粒蛋白定位受到干扰。此外,桥粒基因中的致病性变异的影响反映在颊粘膜细胞 (BMC) 等非心脏组织中,这可能成为一种有前途的新的非侵入性工具来支持诊断。我们收集了 33 名 ACM 患者、17 名 p.Arg14del 患者和 34 名对照者的 BMC,用不同浓度的抗桥粒蛋白抗体标记 BMC,并对其膜标记进行评分。我们发现,与对照组相比,诊断为 ACM 的患者和临床前变异携带者的 BMC 中桥粒蛋白水平显著降低。这种效应与年龄和性别无关。与常用的 ACM 诊断修订版 2010 工作组标准评分 (r = -0.67, = 64, < 0.0001 和 r = -0.71, = 64, < 0.0001) 呈中度至强相关性。相比之下, p.Arg14del 患者的桥粒蛋白评分与对照组相似 ( > 0.209),这表明潜在病因不同。然而,对于“经典” ACM 患者的个体诊断,由于个体间的高度变异性,这种方法可能不足以区分真正的患者与变异携带者和对照者。